Claims for Patent: 6,124,448

Summary for Patent: 6,124,448

Title:	Nucleic acid primers and probes for the mammalian OB gene
Abstract:	The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polymerase chain reaction (PCR) amplification, i.e., synthetic or natural oligonucleotides. In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention, operatively associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or a mammalian cell transfected or transformed with an appropriate expression vector, and correspondingly, to the use of the above mentioned constructs in the preparation of the modulators of the invention. Also provided are antibodies to the ob polypeptide. Moreover, a method for modulating body weight of a mammal is provided. In specific examples, genes encoding two isoforms of both the murine and human ob polypeptides are provided.
Inventor(s):	Friedman; Jeffrey M. (New York, NY), Zhang; Yiying (New York, NY), Proenca; Ricardo (Astoria, NY), Maffei; Margherita (New York, NY)
Assignee:	The Rockfeller University (NY)
Application Number:	08/488,208
Patent Claims:	1. An isolated nucleic acid of at least 10 nucleotides hybridizable under moderate stringency conditions to a non-coding region of an OB nucleic acid, which non-coding region is selected from the group consisting of an intron, a 5' non-coding region, and a 3' non-coding region of SEQ ID NOS: 1, 3, 22 or 24. 2. An oligonucleotide primer of at least 10 nucleotides for amplifying mouse or human genomic DNA encoding an OB polypeptide, said primer hybridizable under moderate stringency conditions to any of SEQ ID NOS: 1, 3, 22 or 24. 3. An oligonucleotide according to claim 2 which is selected from the group consisting of: HOB 1gF 5'-CCCAAGAAGCCCATCCTG-3' (SEQ ID NO. 29); HOB 1gR 5'-GACTATCTGGGTCCAGTGCC-3' (SEQ ID NO. 30); HOB 2gF 5'-CCACATGCTGAGCACTTGTT-3' (SEQ ID NO. 31); and HOB 2gR 5'-CTTCAATCCTGGAGATACCTGG-3' (SEQ ID NO. 32). 4. A detectably labeled nucleic acid molecule of at least 10 nucleotides hybridizable under moderate stringency conditions to a non-coding region of an OB nucleic acid, which non-coding region is selected from the group consisting of an intron, a 5' non-coding region, and a 3' non-coding region of SEQ ID NOS: 1, 3, 22 or 24.

Details for Patent 6,124,448

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-09-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-09-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-09-26